FDA Class II Recall: Eugia US LLC's Tirofiban Hydrochloride Injection Faces Quality Scrutiny
Eugia US LLC has initiated a Class II nationwide recall for 18,867 bags of Tirofiban Hydrochloride Injection due to out-of-specification results in stability studies for related substances. This event signals critical quality control deficiencies impacting a key cardiovascular drug. Procurement and regulatory teams must assess immediate supply chain risks and re-evaluate supplier qualification protocols to mitigate disruption and ensure patient safety.
FDA Initiates Class II Recall for Eugia US LLC's Tirofiban Hydrochloride Injection
Eugia US LLC has initiated a voluntary, firm-initiated Class II recall for 18,867 bags of its Tirofiban Hydrochloride Injection, a critical human prescription drug used intravenously. This nationwide recall, designated D-0389-2025, commenced on April 21, 2025, following the discovery of out-of-specification (OOS) test results for related substances during a three-month stability study under long-term conditions. The affected product, specifically Lot #: 3TF24002A with an expiration date of November 30, 2026, is packaged as 5 mg/100 mL (50 mcg/mL) in 100 mL single-dose containers, identified by NDC 55150-429-01 and 55150-430-01. This recall directly impacts procurement directors and supply chain VPs reliant on Eugia US LLC for Tirofiban supply, necessitating immediate inventory assessment and contingency planning to prevent stock-outs. The Class II classification indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote, but the OOS finding for related substances points to a fundamental quality control lapse that demands attention from regulatory affairs heads.
Commercial Repercussions of Quality Control Lapses in Pharmaceutical Manufacturing
The OOS stability results for related substances in Eugia US LLC's Tirofiban Hydrochloride Injection underscore significant commercial and regulatory risks for the global chemical and life sciences industry. For business development executives, this event highlights the imperative of rigorous due diligence when evaluating potential partners, especially those involved in manufacturing critical care drugs like Tirofiban. A failure in stability testing, particularly for related substances, indicates potential degradation or impurity issues that can compromise drug efficacy and patient safety. While the product is distributed by Eugia U.S. LLC from East Windsor, NJ, the manufacturing origin in India suggests that quality oversight across the global supply chain is paramount. This incident necessitates that procurement directors reassess their supplier qualification programs, focusing on robust stability data review and comprehensive quality agreements. Regulatory affairs heads must anticipate heightened scrutiny from the FDA on Eugia US LLC's quality management systems, potentially extending to other products under ANDA216379 or other applications, impacting future market access and product approvals. The financial burden of a nationwide recall, including logistics, communication, and potential market share loss, directly impacts a company's profitability and competitive standing.